JAIN, Mukul,JOHARAPURKAR, Amit Arvind,PATEL, Vishal Jagjivanbhai
申请号：
IBIB2016/057091
公开号：
WO2017/089980A1
申请日:
2016.11.24
申请国别(地区):
WO
年份:
2017
代理人:
摘要：
The present invention relates to the use of Saroglitazar or a pharmaceutically acceptable salt thereof, for the treatment of, or the prevention, delay of progression, or treatment of a disease or condition related with disorders of the eye. The disorders of the eye is selected from ocular inflammation, corneal inflammation, diabetic retinopathy (DR), diabetic macular edema, macular degeneration (including, but not limited to, age related macular degeneration), uveitis, retinal inflammation, retinal vascular leakage, retinal neovascularization, cancer, and other inflammatory and neovascular disorders of the eye. The present invention further relates to the use of a pharmaceutical composition comprising Saroglitazar, or a pharmaceutically acceptable salt thereof, for the prevention, delay of progression, or treatment of a disease or condition which is selected from ocular inflammation, corneal inflammation, diabetic retinopathy (DR), diabetic macular edema, macular degeneration (including, but not limited to, age related macular degeneration), uveitis, retinal inflammation, retinal vascular leakage, retinal neovascularization, cancer, and other inflammatory and neovascular disorders of the eye.La présente invention concerne lutilisation de saroglitazar ou dun sel pharmaceutiquement acceptable de celui-ci pour traiter, prévenir ou retarder la progression dune maladie ou dun état lié(e) à des troubles de lœil. Les troubles de lœil sont choisis parmi linflammation oculaire, linflammation de la cornée, la rétinopathie diabétique (RD), lœdème maculaire diabétique, la dégénérescence maculaire (y compris, mais sans sy limiter, la dégénérescence maculaire liée à lâge), luvéite, linflammation de la rétine, la fuite vasculaire rétinienne, la néovascularisation rétinienne, le cancer ainsi que dautres maladies inflammatoires et troubles néovasculaires de lœil. La présente invention concerne également lutilisation dune composition pharmaceutique comprenant du saroglitazar ou un se
